- Home
- CUE vs TORO Comparison
CUE vs TORO Comparison
Compare CUE & TORO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- TORO
- Stock Information
- Founded
- CUE 2014
- TORO 2022
- Country
- CUE United States
- TORO Cyprus
- Employees
- CUE N/A
- TORO N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- TORO Marine Transportation
- Sector
- CUE Health Care
- TORO Consumer Discretionary
- Exchange
- CUE Nasdaq
- TORO Nasdaq
- Market Cap
- CUE 77.3M
- TORO 62.4M
- IPO Year
- CUE 2018
- TORO N/A
- Fundamental
- Price
- CUE $1.07
- TORO $3.01
- Analyst Decision
- CUE Strong Buy
- TORO
- Analyst Count
- CUE 5
- TORO 0
- Target Price
- CUE $5.00
- TORO N/A
- AVG Volume (30 Days)
- CUE 378.2K
- TORO 68.9K
- Earning Date
- CUE 11-14-2024
- TORO 02-10-2025
- Dividend Yield
- CUE N/A
- TORO N/A
- EPS Growth
- CUE N/A
- TORO N/A
- EPS
- CUE N/A
- TORO 0.99
- Revenue
- CUE $9,532,000.00
- TORO $80,626,531.00
- Revenue This Year
- CUE $105.39
- TORO N/A
- Revenue Next Year
- CUE N/A
- TORO N/A
- P/E Ratio
- CUE N/A
- TORO $1.04
- Revenue Growth
- CUE 149.53
- TORO 52.03
- 52 Week Low
- CUE $0.45
- TORO $2.25
- 52 Week High
- CUE $3.20
- TORO $6.45
- Technical
- Relative Strength Index (RSI)
- CUE 45.52
- TORO 59.27
- Support Level
- CUE $0.92
- TORO $2.91
- Resistance Level
- CUE $1.09
- TORO $3.20
- Average True Range (ATR)
- CUE 0.11
- TORO 0.19
- MACD
- CUE 0.00
- TORO 0.09
- Stochastic Oscillator
- CUE 45.71
- TORO 80.42
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
About TORO Toro Corp.
Toro Corp acquires, owns, charters, and operates oceangoing tanker vessels and provides seaborne transportation services for crude oil and refined petroleum products. It operates in three reportable segments: the Aframax tanker, the LPG carrier segment, and the Handysize tanker. The company generates maximum revenue from the Aframax tanker segment.